Navigation Links
Neurologix Reports Third Quarter 2010 Financial Results
Date:11/12/2010

Litigation Reform Act of 1995. These forward-looking statements and other information relating to the Company are based upon the beliefs of management and assumptions made by and information currently available to the Company. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, or performance, as well as underlying assumptions and statements that are other than statements of historical fact. When used in this document, the words "expects," "promises," "anticipates," "estimates," "plans," "intends," "projects," "predicts," "believes," "may" or "should," and similar expressions, are intended to identify forward-looking statements. These statements reflect the current view of the Company's management with respect to future events. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, but not limited to, the following:

  • The Company is still in the development stage and has not generated any revenues. From inception through September 30, 2010, it incurred net losses and negative cash flows from operating activities of approximately $58 million and $43 million respectively. Management believes that the Company will continue to incur net losses and cash flow deficiencies from operating activities for the foreseeable future. Because it may take years to develop, test and obtain regulatory approval for a gene-based therapy product before it can be sold, the Company likely will continue to incur significant losses for the foreseeable future. Accordingly, it may never be profitable and, if it does become profitable, it may be unable to sustain profitability.
  • At September 30, 2010, the Company had cash and cash equivalents of approximately $3 million. Based on its cash flow projections, the Company w
    '/>"/>

  • SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
    2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
    3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    4. Spherix Reports Second Quarter Earnings
    5. Tapestry Reports Second Quarter 2007 Results
    6. Callisto Reports on Second-Quarter 2007 Milestones
    7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
    8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
    9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
    10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    11. Biopure Reports on Meeting with the FDA
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... July 30, 2015 Edwards Lifesciences Corporation (NYSE: ... valves and hemodynamic monitoring, today announced that Robert A. ... "Bob is an ardent champion for innovation in ... to have him on Edwards, board as we pursue our ... chairman and CEO.  "Bob has provided a valuable perspective to ...
    (Date:7/30/2015)... July 30, 2015  Tandem Diabetes Care®, Inc. ... and manufacturer of the t:slim® and t:flex™ Insulin ... non-exclusive Development Agreements with Dexcom, Inc. to allow ... with the Dexcom G5 and G6 continuous glucose ... generation pump platform with Dexcom,s future CGM systems ...
    (Date:7/30/2015)... THOUSAND OAKS, Calif., July 30, 2015  Amgen ... for the second quarter of 2015. Key results ... versus the second quarter of 2014 to $5,370 ... primarily by Enbrel ® (etanercept), Prolia ® ... (carfilzomib) and XGEVA ® (denosumab). Unfavorable ...
    Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
    ... ANTIPOLIS, France, May 11, 2007 /PRNewswire-FirstCall/ --,NicOx S.A. ... phase 2a,study for NCX 1000, which is covered ... A preliminary analysis of 11 patients,from this proof-of-concept ... NCX 1000 but did not demonstrate the efficacy,required ...
    ... 2007--Sciele Pharma, Inc.,(NASDAQ:SCRX) today announced the successful completion ... formulation. The study,results showed that the new Sular ... new Sular formulation,utilizes SkyePharma's (LSE:SKP) patented Geomatrix technology,which ... Sular for each of its,current doses. , The ...
    Cached Medicine Technology:NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 2NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 3Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 2Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 3Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 4
    (Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot ... their new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) ... To commemorate introduction of this new type of sod, Super-Sod is giving away red ...
    (Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s ... It was also the first provider of Exilis non-surgical fat reduction in New York. ... it has attracted a large International clientele. Many patients travel to New York ...
    (Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical ... PRO this week. Zeltiq Aesthetics released this new applicator in the United States ... for treating the outer thighs. The original applicator required a 2 hour treatment ...
    (Date:7/31/2015)... , ... July 31, 2015 , ... Coco Libre announced ... judges, media, and VIPs at the 2015 Vans US Open of Surfing, July 25 ... that can claim “no added sugar” on the market, is a natural choice given ...
    (Date:7/31/2015)... ... , ... According to an article published July 2 on Healio, ... a consensus on the steps that need to be taken to successfully complete several ... consensus on a series of steps that each surgeon must complete for each procedure. ...
    Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
    ... has joined the,MassMutual Retirement Services Division,s institutional sales ... is based in Texas,and supports MassMutual,s third party ... He joins MassMutual from John Hancock where he ... company,s retirement plan services,business. Ambrose has more than ...
    ... must be at play to raise women,s risk, researchers say ... to hike the risk of cardiovascular disease, but don,t put ... So concludes a study led by Dr. Viola Vaccarino, a ... means that it,s back to the drawing board in terms ...
    ... November, 2007 Reproductive Health Matters and Elsevier are pleased ... the celebration of the twentieth anniversary of the Safe Motherhood ... November issue responds to the question Is Pregnancy Getting ... no. , Globally, the maternal mortality ...
    ... ... Diabetes Day, MARLBOROUGH, Mass., ... medical technology company for the design,development, manufacturing and marketing of retinal ... 2007. On this,one day over 100 eye care practices throughout North ...
    ... Nov. 15 Every year more,holiday shoppers look ... above the rest while helping families in need. ... taken this,charitable holiday gift-giving approach to heart offering ... . Mercy Kits give people the opportunity ...
    ... have to get into a,cold bed again with an ... too heated up by all of the choices available. ... are more options to choose from than ever before,",according ... http://www.comforthouse.com ). Gornstein evaluates dozens of new electric,blankets and ...
    Cached Medicine News:Health News:Inflammation Can't Explain Depression's Link to Heart Disease 2Health News:November issue of Reproductive Health Matters focuses on maternal mortality 2Health News:Free Diabetes Eye Screenings Taking Place in Recognition of World Diabetes Day 2Health News:Online Charitable Holiday Giving: Making a Difference with the Gifts You Give 2Health News:What's New in Electric Blankets and Heated Mattress Pads 2
    ... standard in corneal diagnostics. Precise Display ... membrane, stroma, Bowman's membrane and epithelial ... Broad Applications in Surgery and Pathology. ... evaluation, endothelial cell analysis, haze detection, ...
    ... appearance of photo-aged skin, removes age spots ... and broken capillaries. This innovative new application ... pigmentary sun damage through a process called ... and the Nd:YAG Laser is optimized for ...
    ... affordable lenses available in a variety ... available in prescription powers for those ... "Plano" for those who don't. They ... technology. Incredibly comfortable, 10 fun, eye-catching ...
    Each jet black lens features a mesmerizing thin white line that spirals toward the center of the pupil....
    Medicine Products: